Bevacizumab for Central Retinal Vein Occlusion Study

A Prospective, Randomized, Controlled Study on Intravitreal Bevacizumab (Avastin) for Central Retinal Vein Occlusion (CRVO)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00906685

Enrollment

Registered

2009-05-21

Start date

2009-05-31

Completion date

2011-09-30

Last updated

2011-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Retinal Vein Occlusion

Keywords

CRVO, anti-VEGF, Macular edema

Brief summary

Central retinal vein occlusion is a leading cause of severe visual impairment. Until now, no treatment has been available to improve visual acuity. The present study intends to investigate if intravitreal bevacizumab can improve visual acuity as compared to sham-treated control patients.

Interventions

DRUGbevacizumab

Intravitreal injection of 1.25 mg bevacizumab

DRUGSham bevacizumab injection

Sham intravitreal injection

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* CRVO with duration \< 6 months * Visual acuity of 20/800 to 20/50

Exclusion criteria

* CRVO with duration of \> 6 months * previous treatment with anti-angiogenic drugs

Design outcomes

Primary

Measure	Time frame
The proportion of patients gaining 15 ETDRS letters or more	6 months

Secondary

Measure	Time frame
Change in foveal thickness	6 months
Cases of neovascular glaucoma	6 months

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026